Molecular Pathway Reveals Driver of Triple-Negative Breast Cancer Spread
Posted on 24 Aug 2026
Triple-negative breast cancer (TNBC) is among the most aggressive breast cancer subtypes and lacks hormone receptors and HER2, limiting targeted treatment options. Its tendency to spread rapidly and relapse contributes substantially to breast cancer mortality, underscoring the need for reliable markers of metastatic risk and interventions that can halt early tumor outgrowth. Addressing these needs, a new study identifies a microRNA-governed pathway that may help predict metastatic progression and guide strategies to curb TNBC spread.
Adelaide University researchers, working with the Olivia Newton-John Cancer Research Institute, identified a targetable miR-342–E2F network that functions as a molecular switch for TNBC metastasis. The team found that patients with low levels of the naturally occurring microRNA miR-342 and high activity in the E2F pathway were more likely to develop metastatic disease. The work, published in EMBO Molecular Medicine on August 21, 2026, positions the miR-342–E2F axis as a mechanistic driver rather than a passive correlate of spread.
Mechanistically, miR-342 acts as a master regulator of genes involved in cancer progression. When miR-342 levels decline, the E2F pathway becomes overactive, allowing dormant disseminated tumor cells to resume growth and form secondary lesions. In preclinical models, restoring miR-342 markedly reduced metastatic spread to distant organs, including the lungs and bones, underscoring the pathway’s central role in controlling metastatic outgrowth.
The researchers also evaluated cyclin-dependent kinase (CDK) 4/6 inhibition in this context. In models characterized by low miR-342, the CDK4/6 inhibitor palbociclib significantly reduced growth of metastatic tumors, with particular effectiveness when administered after cancer cells had already disseminated, preventing microscopic metastases from expanding.
According to the authors, measuring miR-342 levels could help identify a subgroup of women with TNBC who are most likely to benefit from CDK4/6 inhibitors, indicating a potential biomarker-driven approach.
“Rather than shrinking the primary tumour, this treatment may prove most valuable by stopping tiny metastatic deposits from developing into life-threatening secondary cancers. Our study identifies a distinct subgroup of patients whose cancers share a common biological weakness, opening the door to a much more personalised treatment approach,” said Professor Robin Anderson, co-senior author, Olivia Newton-John Cancer Research Institute.
Related Links
Centre for Cancer Biology – Adelaide University
Olivia Newton-John Cancer Research Institute
